Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Responsiveness and minimal important differences for patient reported outcomes.

Dennis A Revicki1, David Cella, Ron D Hays

  • 1Center for Health Outcomes Research, United Biosource Corporation, 7101 Wisconsin Ave., Suite 600, Bethesda, MD 20814, USA. dennis.revicki@unitedbiosource.com

Health and Quality of Life Outcomes
|September 29, 2006
PubMed
Summary

Patient reported outcomes (PROs) are crucial for treatment effectiveness. Clarifying methods for determining PRO responsiveness and minimal important differences (MIDs) is essential for reliable clinical trial endpoints and claims.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate.

The Journal of community and supportive oncology·2016
Same author

Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3.

PharmacoEconomics·2016
Same author

Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.

Current medical research and opinion·2016
Same author

Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer.

Clinical therapeutics·2016
Same author

Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2016
Same author

Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Cancer·2016

Area of Science:

  • Clinical research methodology
  • Health outcomes measurement
  • Patient-centered care

Background:

  • Patient reported outcomes (PROs) offer vital patient perspectives on treatment effectiveness.
  • Draft Food and Drug Administration (FDA) guidance highlights the need for methodological clarity in PRO use for claims.
  • Key issues include determining PRO responsiveness and minimal important differences (MIDs).

Purpose of the Study:

  • To address method and measurement issues in the FDA's draft guidance on PROs.
  • To clarify the requirements for PRO instruments used in clinical trials.
  • To define best practices for establishing responsiveness and MIDs for PRO effectiveness endpoints.

Main Methods:

  • Instruments require a clear conceptual framework, content validity, and sound psychometric properties.

Related Experiment Videos

  • Responsiveness must be demonstrated using anchor-based methods and supported by distribution-based estimates.
  • Triangulation of multiple methods is recommended to establish a single MID value or narrow range.

    • Main Results:

    • Establishing a robust MID requires evidence from multiple anchor-based and distribution-based methods.
    • Confidence in an MID increases with supporting research and clinical trial experience.
    • MIDs are context- and population-specific, necessitating tailored validation for each PRO instrument and study.

    Conclusions:

    • Demonstrating PRO responsiveness and MIDs is critical for their use as effectiveness endpoints.
    • Validated PRO measures with documented responsiveness and MIDs are necessary for labeling and promotional claims.
    • Further research and clinical experience are needed to build confidence in specific MID values.